ELIQUIS (apixaban) 5mg tablets by Bristol-Myers Squibb and Pfizer Bristol-Myers Squibb and Pfizer announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application ...
Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...
Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...
ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One ...
Credit: Getty Images. The recall is specific to Eliquis 5mg Tablets (60-count bottle) Lot# HN0063 with expiration date of September 2019. Bristol-Myers Squibb is recalling one lot of Eliquis (apixaban ...
MedPage Today on MSN
Apixaban snags a win in head-to-head trial of direct oral anticoagulants
Favorable safety shown in secondary prevention for acute venous thromboembolism ...
Choice of direct oral anticoagulant (DOAC) mattered for clinical outcomes among adults with atrial fibrillation (Afib), a study based on U.S. insurance claims found. Apixaban (Eliquis) users had ...
The trial enrolled patients with cryptogenic stroke and evidence suggestive of atrial cardiopathy, but no evidence of atrial fibrillation, who were randomized to apixaban, 5 mg or 2.5 mg twice daily, ...
In the ARISTOTLE trial of apixaban versus warfarin for stroke prevention in patients with atrial fibrillation, those with two or more dose-reduction criteria (aged ≥80 years, weight ≤60 kg, creatinine ...
Apotex, a Canadian manufacturer of generics, recently introduced APO-Apixaban tablets, Canada's first generic alternative to Bristol-Myers Squibb’s Eliquis. Apotex's apixaban is an oral anticoagulant ...
Please provide your email address to receive an email when new articles are posted on . Asundexian did not prevent stroke or systemic embolism vs. apixaban in patients with atrial fibrillation despite ...
VICTORIA, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Major health risks stemming from blood clots moving through arteries and into the heart, lungs, brain or other organs of the body are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results